WO2023206607A1 - Method for preparing oxacephem parent nucleus intermediate - Google Patents
Method for preparing oxacephem parent nucleus intermediate Download PDFInfo
- Publication number
- WO2023206607A1 WO2023206607A1 PCT/CN2022/092235 CN2022092235W WO2023206607A1 WO 2023206607 A1 WO2023206607 A1 WO 2023206607A1 CN 2022092235 W CN2022092235 W CN 2022092235W WO 2023206607 A1 WO2023206607 A1 WO 2023206607A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acb
- reaction
- oxycephem
- preparing
- temperature
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- QXNSHVVNEOAAOF-RXMQYKEDSA-N (6R)-4-oxa-5-thia-1-azabicyclo[4.2.0]oct-2-en-8-one Chemical compound S1OC=CN2[C@H]1CC2=O QXNSHVVNEOAAOF-RXMQYKEDSA-N 0.000 title abstract 2
- 238000006243 chemical reaction Methods 0.000 claims abstract description 84
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 239000002904 solvent Substances 0.000 claims abstract description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 195
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 16
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(I) oxide Inorganic materials [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 claims description 14
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 claims description 14
- 229940112669 cuprous oxide Drugs 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 239000000376 reactant Substances 0.000 claims description 6
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 5
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 238000000746 purification Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 59
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 34
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 32
- 238000003756 stirring Methods 0.000 description 32
- 239000000543 intermediate Substances 0.000 description 25
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 19
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 17
- 239000008213 purified water Substances 0.000 description 17
- 235000017557 sodium bicarbonate Nutrition 0.000 description 17
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 17
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 16
- 235000019341 magnesium sulphate Nutrition 0.000 description 16
- 239000012071 phase Substances 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 235000010265 sodium sulphite Nutrition 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 10
- 229910015900 BF3 Inorganic materials 0.000 description 8
- 239000002994 raw material Substances 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 239000003513 alkali Substances 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 238000009776 industrial production Methods 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 235000009518 sodium iodide Nutrition 0.000 description 6
- 239000012295 chemical reaction liquid Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005660 chlorination reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- IWYVYUZADLIDEY-UHFFFAOYSA-N 4-methoxybenzenesulfonic acid Chemical compound COC1=CC=C(S(O)(=O)=O)C=C1 IWYVYUZADLIDEY-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000003518 caustics Substances 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- -1 Hept-2-en-6-yl Chemical group 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000746 allylic group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
- C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
- C07D505/16—Nitrogen atoms
- C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D505/02—Preparation
- C07D505/04—Preparation by forming the ring or condensed ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention belongs to the technical field of pharmaceutical and chemical engineering, and specifically relates to a preparation method of oxycephem core intermediate.
- Oxycephem core intermediate is an important intermediate for the preparation of fluoxycephalosporin and laoxycephalosporin.
- This type of antibiotic has a structure similar to cephalosporins of oxycephem antibiotics, and its antibacterial spectrum is similar to other third-generation cephalosporins. Such as laxacephalosporin and flurocephalosporin.
- This type of drug has a strong effect on anaerobic bacteria and is used for respiratory tract infections, urinary tract infections, gynecological infections, surgical infections and otolaryngology infections. It has broad application prospects and huge demand at home and abroad.
- Patent JP2005179336 discloses the following synthetic route of oxycephem core intermediate:
- the reaction is a discontinuous reaction, and the reaction The steps are complicated, the cycle is long, the cost is high, and the reaction yield is only 54%, which is not conducive to industrial production.
- the reaction uses boron trifluoride, a highly corrosive substance, which is already a restricted substance in the current field of chemical medicine.
- Patent CN103254215B discloses the following synthetic route of oxycephem core intermediate:
- This reaction involves the addition of chlorine gas, causing the double bond at the allyl position to undergo an addition reaction with chlorine gas to obtain a dichloride product, which is then subjected to elimination reaction, hydrolysis reaction, and ring-closing reaction to obtain the key intermediate of the oxyhead-based antibiotics.
- This reaction involves the addition of chlorine gas, causing the double bond at the allyl position to undergo an addition reaction with chlorine gas to obtain a dichloride product, which is then subjected to elimination reaction, hydrolysis reaction, and ring-closing reaction to obtain the key intermediate of the oxyhead-based antibiotics.
- this The structure of the relevant intermediates in the route is different, avoiding the exposure of the double bond at the propylene position.
- the allylic position chlorination reaction of this synthesis route uses chlorosuccinimide as the chlorination reagent, and the allylic position chlorination is a free radical reaction.
- the reaction activity of chlorosuccinimide is not as good as that of chlorine gas, and its price is more expensive than chlorine gas. This results in higher production costs, the two methyl groups at the allyl position are more likely to undergo multiple substitution side reactions, and the reaction selectivity is poor.
- boron trifluoride complex a highly corrosive substance, is used to catalyze the reaction, which is already a restricted substance in the current field of chemical medicine.
- the invention provides a preparation method of ACB-7, which continuously prepares ACB-7 from ACB-3.
- the reaction route is as follows:
- ACB-3, ACB-4, ACB-5, and ACB-7 are the codes of the corresponding compounds respectively.
- ACB-3 is 3-methyl-2-(7-oxo-3-p-tolyl-4-oxa-2,6-diazabicyclo[3.2.0]
- ACB-7 is 3-methylene-7-[(4-methylbenzoyl)amino]-8-oxo-5-oxa-1-azabicyclo[4.2.0]octane-2- diphenylmethylcarboxylate
- the embodiments of the present invention provide a variety of specific operating steps for continuously producing ACB-7 from ACB-3.
- the present invention provides a method for continuously preparing ACB-7 from ACB-3.
- the key to the continuous preparation is that the yield and purity of the products in each intermediate step are high enough, so each reaction parameter needs to be strictly controlled.
- the product yield of ACB-4 produced from ACB-3 (mass ratio of ACB-4 to ACB-3) can reach 91.5%, and the purity can reach 98.6%.
- the reaction solvent is preferably Ethyl acetate or methylene chloride, more preferably ethyl acetate.
- the mass ratio between ACB-3 and solvent is 1: (10-20).
- the temperature is controlled at 30-45°C, and the reaction time is 1-3h.
- the product yield of ACB-5 produced from ACB-4 (mass ratio of ACB-5 to ACB-4) can reach 96.5%, and the purity can reach 99.0%.
- the iodide is preferably NaI or KI.
- the reaction solution is stirred for 1-2h, preferably 1.5-2h, and the temperature is controlled to 20-45°C, preferably 30-35°C.
- the reaction solvent is preferably ethyl acetate or acetone, and the mass ratio between ACB-4 and the solvent ethyl acetate or acetone is 1: (3-10).
- iodide can be recycled and reused, further saving industrial costs.
- the product yield of ACB-7 produced from ACB-5 (mass ratio of ACB-7 to ACB-5) can reach 96.5%, and the purity can reach 98.8%.
- ACB-7 (such as the technical solution disclosed in JP2005179336, the background technology of the present invention).
- the chemical structure of ACB-6 is as follows:
- the present invention unexpectedly discovered during the research and development process of preparing ACB-6 from ACB-5 that when only cuprous oxide/dimethyl sulfoxide/benzenesulfonic acid acidic catalyst was added to the reactants without adding water, the reaction product Some of the peaks in the detection are shown to be ACB-7 (see Figure 7).
- the inventor speculates that ACB-7 can be prepared from ACB-5 in one step, thus avoiding the preparation of hydroxyl compounds such as hydroxyl compounds in a water environment in the prior art. After ACB-6, the hydroxyl compounds need to be extracted and then ring-closed in an anhydrous environment, and the use of strong acid such as boron trifluoride for catalytic ring-closure is avoided. Therefore, by controlling precise reaction conditions, the present invention can convert ACB-5 into ACB-7 in one step with high efficiency and high yield, with low cost and simple operation, and avoids the use of boron trifluoride.
- the above-mentioned benzenesulfonic acid acidic catalyst may be any one of p-toluenesulfonic acid, benzenesulfonic acid, and p-methoxybenzenesulfonic acid.
- the temperature of the above reaction adopts step temperature. When the initial temperature is controlled at 10-15°C, the reaction will last for 2-3 hours, and then when the temperature is raised to 40-60°C, the reaction will take 0.5-2 hours.
- the temperature rise temperature is preferably 45-55°C.
- the reactant ratio is calculated based on ACB-5.
- the mass ratio of ACB-5 to p-toluenesulfonic acid is 1: (0.02-0.45), preferably 1: (0.02-0.12).
- the mass ratio of ACB-5 to solvent dimethyl sulfoxide is 1: (6-10).
- the mass ratio of ACB-3 to cuprous oxide is 1: (0.27-0.45).
- the reactant ratio is calculated based on ACB-3.
- the mass ratio of ACB-3 to p-toluenesulfonic acid is 1: (0.03-0.5), preferably 1: (0.03-0.15); ACB-3 and solvent dimethyl
- the mass ratio of base sulfoxide is 1: (5-15); the mass ratio of ACB-3 to cuprous oxide is 1: (0.2-0.5).
- the crystallization operation steps need to be optimized.
- the preferred crystallization solvent is: one of methanol, ethanol, isopropyl alcohol, n-hexane, and ethyl acetate, with methanol being preferred.
- Optimal solvent ratio is: one of methanol, ethanol, isopropyl alcohol, n-hexane, and ethyl acetate, with methanol being preferred.
- the mass ratio of the crystallization solvent to ACB-3 is: 1: (3-6), preferably 1: (1-4).
- the mass ratio of the crystallization solvent to ACB-3 is: 1: (1-5), preferably 1: (1-4).
- the present invention also provides a method for preparing ACB-7 from ACB-5.
- the embodiments of the present invention provide specific operating steps for preparing ACB-7 from ACB-5 in one step.
- the preferred solvent for the entire process of continuously producing ACB-7 from ACB-3 provided by the present invention is ethyl acetate.
- the ethyl acetate solvent can also be recycled.
- the ethyl acetate solution of ACB-5 can be partially evaporated for reuse. The specific evaporation amount is determined based on the principle of convenience for process use. For example, it is generally evaporated until about half of the solution is retained.
- the invention provides a method for preparing an oxycephem core intermediate, which continuously prepares ACB-7 from ACB-3.
- the operation is simple, the intermediate links for purification are reduced through continuous reactions, and the yield is improved. Moreover, the solvent can be recycled and the reaction The process also avoids the use of highly toxic or corrosive reagents, and ultimately obtains the target product in high yield. This technology has been successfully used in industrial production and has very high economic and environmental value.
- Figure 1 is the HPLC spectrum of the product ACB-7 of Example 1.1.
- Figure 2 is the NMR spectrum of the product ACB-7 of Example 1.1.
- Figure 3 is the HPLC spectrum of the product ACB-4 of Example 3.1.
- Figure 4 is the nuclear magnetic resonance spectrum of the product ACB-4 of Example 3.1.
- Figure 5 is the HPLC spectrum of the product ACB-5 of Example 4.1.
- Figure 6 is the nuclear magnetic resonance spectrum of the product ACB-5 of Example 4.1.
- Figure 7 is a diagram of the reaction process of preparing ACB-7 from ACB-5 according to the present invention.
- the oxycephem core intermediate ACB-7 is 70.4g in white powder form, with a purity of 98.4% and a total yield of 76.9%.
- the product oxycephem core intermediate ACB-7 is 76.9g in the form of white powder, with a purity of 98.6% and a total yield of 83.9%.
- the following table shows the yield and purity results of ACB-7 obtained by adjusting various process parameters.
- the yield is the mass ratio of ACB-7 to ACB-5.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The present invention provides a method for preparing an oxacephem parent nucleus intermediate. ACB-7 is continuously prepared from ACB-3, or ACB-7 is directly prepared from ACB-5. The preparation method of the present invention is simple to operate, intermediate steps for purification are reduced through by means of continuous reaction for purification, the yield is increased, the solvent can be recycled, a highly toxic or strongly corrosive reagent is prevented from being used in the reaction process, and finally a target product is obtained with a high yield.
Description
本发明属于医药化工技术领域,具体涉及氧头孢烯母核中间体的制备方法。The invention belongs to the technical field of pharmaceutical and chemical engineering, and specifically relates to a preparation method of oxycephem core intermediate.
氧头孢烯母核中间体是制备氟氧头孢和拉氧头孢重要的中间体,该类抗生素具有氧头孢烯类抗生素的结构类似头孢菌素,其抗菌谱和其它第三代头孢菌素相似,如拉氧头孢和氟氧头孢。本类药物对厌氧菌有较强作用,用于呼吸道感染,尿路感染,妇科感染,外科感染及耳鼻喉科感染等,应用前景十分广阔,国内外需求巨大。Oxycephem core intermediate is an important intermediate for the preparation of fluoxycephalosporin and laoxycephalosporin. This type of antibiotic has a structure similar to cephalosporins of oxycephem antibiotics, and its antibacterial spectrum is similar to other third-generation cephalosporins. Such as laxacephalosporin and flurocephalosporin. This type of drug has a strong effect on anaerobic bacteria and is used for respiratory tract infections, urinary tract infections, gynecological infections, surgical infections and otolaryngology infections. It has broad application prospects and huge demand at home and abroad.
目前国内对氧头孢烯母核中间体的研究较少,而且都是分步拿出部分产品,制备成本高不适合工业化生产。At present, there are few domestic studies on oxycephem core intermediates, and some products are produced step by step. The preparation cost is high and is not suitable for industrial production.
专利JP2005179336公开了如下氧头孢烯母核中间体的合成路线:Patent JP2005179336 discloses the following synthetic route of oxycephem core intermediate:
该氧头孢烯母核中间体与本发明的氧头孢烯母核中间体在分子结构方面有一个对甲基的差别,对反应条件的设计也有了不同的要求;该反应为不连续反应,反应步骤繁琐,周期长,成本高,反应收率只有54%,不利于工业化生产,而且该反应中用到了三氟化硼这种高腐蚀性物质,在当前化学医药领域已经是限制性使用物质。There is a difference in the molecular structure between the oxycephem core intermediate and the oxycephem core intermediate of the present invention in terms of methyl group, and there are also different requirements for the design of reaction conditions; the reaction is a discontinuous reaction, and the reaction The steps are complicated, the cycle is long, the cost is high, and the reaction yield is only 54%, which is not conducive to industrial production. Moreover, the reaction uses boron trifluoride, a highly corrosive substance, which is already a restricted substance in the current field of chemical medicine.
专利CN103254215B中公开了如下氧头孢烯母核中间体的合成路线:Patent CN103254215B discloses the following synthetic route of oxycephem core intermediate:
该反应经氯气加成,使烯丙基位的双键与氯气进行加成反应得到二氯产物,再经过消去反应、水解反应、关环反应得到氧头包烯类抗生素关键中间体,但此路线中相关中间体的结构有所不同,回避了丙烯基位双键的裸露。This reaction involves the addition of chlorine gas, causing the double bond at the allyl position to undergo an addition reaction with chlorine gas to obtain a dichloride product, which is then subjected to elimination reaction, hydrolysis reaction, and ring-closing reaction to obtain the key intermediate of the oxyhead-based antibiotics. However, this The structure of the relevant intermediates in the route is different, avoiding the exposure of the double bond at the propylene position.
浙江工业大学于2018年研究公开的论文《氧头孢烯类抗生素中间体合成工艺研究》中涉及如下氧头孢烯母核中间体的合成路线:The paper "Research on the Synthesis Process of Oxycephem Antibiotic Intermediates" published by Zhejiang University of Technology in 2018 involves the following synthesis route of the oxycephem core intermediate:
该氧头孢烯母核中间体与本发明的氧头孢烯母核中间体在分子结构方面有一个邻甲基的差别,且该合成路线特意规避NaI的使用,但是本专利申请人经过研究实验,发现在双键加成时不可避免地发生烯丙位的氯代,反应杂质较多,收率较低,如不用碘代物,烯丙位氯代位置反应活性较差,水解反应很难高效进行。而且该论文公布的收率也只有57.9%, 并且使用了高腐蚀性物质三氟化硼络合物,并不适合工业化生产。There is an ortho-methyl difference in molecular structure between the oxycephem core intermediate and the oxycephem core intermediate of the present invention, and the synthesis route specifically avoids the use of NaI. However, after research and experiments, the patent applicant has It was found that chlorination of the allyl position inevitably occurs during double bond addition. The reaction has more impurities and a lower yield. If iodide is not used, the reaction activity of the chlorine position of the allyl position is poor, and the hydrolysis reaction is difficult to carry out efficiently. . Moreover, the yield published in this paper is only 57.9%, and the highly corrosive substance boron trifluoride complex is used, which is not suitable for industrial production.
郑州大学在专利CN106188097A中公开了如下氧头孢烯母核中间体的合成路线:Zhengzhou University disclosed the following synthetic route of oxycephem core intermediate in patent CN106188097A:
该合成路线的烯丙位氯化反采用氯代丁二酰亚胺作为氯化试剂,烯丙位氯代为自由基反应,氯代丁二酰亚胺反应活性不如氯气,且价格较氯气昂贵,造成生产成本较高,烯丙位两个甲基更容易发生多取代副反应,反应选择性较差。在最后合环反应中,采用三氟化硼络合物高腐蚀性物质催化反应,在当前化学医药领域已经是限制性使用物质。同时众所周知,三氟化硼反应需要在无水环境中才能进行,而该对比文件显示三氟化硼与水一起催化反应,其反应效果存疑。该对比文件方法虽然宣称七步优化成三步,收率达76%,但总体收率还是偏低,且所用试剂较为昂贵,不适合工业化生产。The allylic position chlorination reaction of this synthesis route uses chlorosuccinimide as the chlorination reagent, and the allylic position chlorination is a free radical reaction. The reaction activity of chlorosuccinimide is not as good as that of chlorine gas, and its price is more expensive than chlorine gas. This results in higher production costs, the two methyl groups at the allyl position are more likely to undergo multiple substitution side reactions, and the reaction selectivity is poor. In the final ring-closing reaction, boron trifluoride complex, a highly corrosive substance, is used to catalyze the reaction, which is already a restricted substance in the current field of chemical medicine. At the same time, it is well known that boron trifluoride reaction needs to be carried out in an anhydrous environment, and this comparison document shows that boron trifluoride catalyzes the reaction with water, and its reaction effect is questionable. Although the reference document method claims that seven steps have been optimized into three steps, with a yield of 76%, the overall yield is still low, and the reagents used are relatively expensive and are not suitable for industrial production.
发明内容Contents of the invention
针对上述问题,有必要对氧头孢烯母核中间体的制备方法进行改进和优化,开发出一种收率较高、成本较低、更适合工业化生产的合成路线。In response to the above problems, it is necessary to improve and optimize the preparation method of oxycephem core intermediate, and develop a synthetic route with higher yield, lower cost and more suitable for industrial production.
本发明提供一种ACB-7的制备方法,由ACB-3连续制得ACB-7,反应路线如下:The invention provides a preparation method of ACB-7, which continuously prepares ACB-7 from ACB-3. The reaction route is as follows:
其中ACB-3、ACB-4、ACB-5、ACB-7分别为对应化合物的代号。Among them, ACB-3, ACB-4, ACB-5, and ACB-7 are the codes of the corresponding compounds respectively.
ACB-3为3-甲基-2-(7-氧代-3-对甲苯基-4-氧杂-2,6-二氮杂双环[3.2.0]ACB-3 is 3-methyl-2-(7-oxo-3-p-tolyl-4-oxa-2,6-diazabicyclo[3.2.0]
庚-2-烯-6-基)-丁-3-烯酸二苯甲基酯Hept-2-en-6-yl)-but-3-enoic acid diphenylmethyl ester
ACB-7为3-亚甲基-7-[(4-甲基苯甲酰)氨基]-8-氧代-5-氧杂-1-氮杂双环[4.2.0]辛烷-2-羧酸二苯甲酯ACB-7 is 3-methylene-7-[(4-methylbenzoyl)amino]-8-oxo-5-oxa-1-azabicyclo[4.2.0]octane-2- diphenylmethylcarboxylate
本发明实施例给出多种从ACB-3连续制得ACB-7的具体操作步骤。The embodiments of the present invention provide a variety of specific operating steps for continuously producing ACB-7 from ACB-3.
本发明提供的一种由ACB-3连续制得ACB-7,其能够实施连续制备关键在于各中间步骤产物的收率和纯度达到足够高,因此需要严格控制各反应参数。The present invention provides a method for continuously preparing ACB-7 from ACB-3. The key to the continuous preparation is that the yield and purity of the products in each intermediate step are high enough, so each reaction parameter needs to be strictly controlled.
具体的,通过各种参数的优化配置,由ACB-3制得ACB-4的产品收率(ACB-4与ACB-3的质量比)可达91.5%,纯度可达98.6%。Specifically, through the optimized configuration of various parameters, the product yield of ACB-4 produced from ACB-3 (mass ratio of ACB-4 to ACB-3) can reach 91.5%, and the purity can reach 98.6%.
氯化物原料优选氯气,ACB-3:氯气摩尔比=1:(1-2.5),优选1:(1-2),1:(1-1.5)或1:(1-1.2);反应溶剂优选乙酸乙酯或二氯甲烷,更优选乙酸乙酯。ACB-3与溶剂之间的质量比为1:(10-20)。温度控制在30-45℃,反应时间为1-3h。The chloride raw material is preferably chlorine, ACB-3: chlorine molar ratio = 1: (1-2.5), preferably 1: (1-2), 1: (1-1.5) or 1: (1-1.2); the reaction solvent is preferably Ethyl acetate or methylene chloride, more preferably ethyl acetate. The mass ratio between ACB-3 and solvent is 1: (10-20). The temperature is controlled at 30-45°C, and the reaction time is 1-3h.
具体的,通过各种参数的优化配置,由ACB-4制得ACB-5的产品收率(ACB-5与ACB-4的质量比)可达96.5%,纯度可达99.0%。Specifically, through the optimized configuration of various parameters, the product yield of ACB-5 produced from ACB-4 (mass ratio of ACB-5 to ACB-4) can reach 96.5%, and the purity can reach 99.0%.
碘化物优选NaI或KI,搅拌反应液1-2h,优选1.5-2h,温度控制为20-45℃,优选30-35℃。The iodide is preferably NaI or KI. The reaction solution is stirred for 1-2h, preferably 1.5-2h, and the temperature is controlled to 20-45°C, preferably 30-35°C.
反应物配比按照ACB-4为基准来核算,ACB-4:碘化物摩尔比=1:(0.8-1.5),优选1:(1-1.5),1:(1-1.2)。The reactant ratio is calculated based on ACB-4, ACB-4: iodide molar ratio = 1: (0.8-1.5), preferably 1: (1-1.5), 1: (1-1.2).
反应物配比按照ACB-3为基准来核算,ACB-3:碘化物摩尔比=1:(1-1.5)。The reactant ratio is calculated based on ACB-3, ACB-3: iodide molar ratio = 1: (1-1.5).
反应溶剂优选乙酸乙酯或丙酮,ACB-4与溶剂乙酸乙酯或丙酮之间的质量比为1:(3-10)。The reaction solvent is preferably ethyl acetate or acetone, and the mass ratio between ACB-4 and the solvent ethyl acetate or acetone is 1: (3-10).
进一步,碘化物可以进行回收再利用,进一步节省工业成本。Furthermore, iodide can be recycled and reused, further saving industrial costs.
具体的,通过各种参数的优化配置,由ACB-5制得ACB-7的产品收率(ACB-7与ACB-5的质量比)可达96.5%,纯度可达98.8%。Specifically, through the optimized configuration of various parameters, the product yield of ACB-7 produced from ACB-5 (mass ratio of ACB-7 to ACB-5) can reach 96.5%, and the purity can reach 98.8%.
对于ACB-5制得ACB-7的步骤,需要进一步说明。现有技术一般由ACB-5通过加入氧化亚铜/二甲基亚砜/酸/水体系,反应制得ACB-6,结晶提纯出ACB-6后再加入三氟化硼催化合环制得ACB-7(如本发明背景技术专利JP2005179336中公开的技术方案)。ACB-6化学结构如下:The steps to prepare ACB-7 from ACB-5 require further explanation. The existing technology generally prepares ACB-6 from ACB-5 by adding cuprous oxide/dimethyl sulfoxide/acid/water system, reacting, crystallizing and purifying ACB-6, and then adding boron trifluoride to catalyze ring closure. ACB-7 (such as the technical solution disclosed in JP2005179336, the background technology of the present invention). The chemical structure of ACB-6 is as follows:
而本发明在从ACB-5制备ACB-6的研发过程中意外的发现,当反应物只添加氧化亚铜/二甲基亚砜/苯磺酸类酸性催化剂,而不添加水时,反应产物的检测中有部分峰显示为ACB-7(参见附图7),本发明人推测从ACB-5可以一步制得ACB-7,而避免了现有技术中在水环境中制得羟基物如ACB-6后,还需要将羟基物提取出来,再在无水环境中进行合环处理,并且避免了使用三氟化硼这种强酸进行催化合环。因此,本发明通过控制精细的反应条件,能够使得ACB-5高效高收率的一步转化为ACB-7,成本低,操作简单,还避免了三氟化硼的使用。The present invention unexpectedly discovered during the research and development process of preparing ACB-6 from ACB-5 that when only cuprous oxide/dimethyl sulfoxide/benzenesulfonic acid acidic catalyst was added to the reactants without adding water, the reaction product Some of the peaks in the detection are shown to be ACB-7 (see Figure 7). The inventor speculates that ACB-7 can be prepared from ACB-5 in one step, thus avoiding the preparation of hydroxyl compounds such as hydroxyl compounds in a water environment in the prior art. After ACB-6, the hydroxyl compounds need to be extracted and then ring-closed in an anhydrous environment, and the use of strong acid such as boron trifluoride for catalytic ring-closure is avoided. Therefore, by controlling precise reaction conditions, the present invention can convert ACB-5 into ACB-7 in one step with high efficiency and high yield, with low cost and simple operation, and avoids the use of boron trifluoride.
上述苯磺酸类酸性催化剂可以为对甲基苯磺酸、苯磺酸、对甲氧基苯磺酸中的任意一种。上述反应的温度采用阶梯温度,初始温度控制在10-15℃时反应2-3h之后,升温至40-60℃时反应0.5-2h,升温温度优选45-55℃。The above-mentioned benzenesulfonic acid acidic catalyst may be any one of p-toluenesulfonic acid, benzenesulfonic acid, and p-methoxybenzenesulfonic acid. The temperature of the above reaction adopts step temperature. When the initial temperature is controlled at 10-15°C, the reaction will last for 2-3 hours, and then when the temperature is raised to 40-60°C, the reaction will take 0.5-2 hours. The temperature rise temperature is preferably 45-55°C.
反应物配比按照ACB-5为基准来核算,ACB-5与对甲基苯磺酸质量比为1:(0.02-0.45),优选1:(0.02-0.12)。ACB-5与溶剂二甲基亚砜的质量比为1:(6-10)。ACB-3与氧化亚铜的质量比为1:(0.27-0.45)。The reactant ratio is calculated based on ACB-5. The mass ratio of ACB-5 to p-toluenesulfonic acid is 1: (0.02-0.45), preferably 1: (0.02-0.12). The mass ratio of ACB-5 to solvent dimethyl sulfoxide is 1: (6-10). The mass ratio of ACB-3 to cuprous oxide is 1: (0.27-0.45).
反应物配比按照ACB-3为基准来核算,ACB-3与对甲基苯磺酸质量比为1:(0.03-0.5),优选1:(0.03-0.15);ACB-3与溶剂二甲基亚砜的质量比为1:(5-15);ACB-3与氧化亚铜的质量比为1:(0.2-0.5)。The reactant ratio is calculated based on ACB-3. The mass ratio of ACB-3 to p-toluenesulfonic acid is 1: (0.03-0.5), preferably 1: (0.03-0.15); ACB-3 and solvent dimethyl The mass ratio of base sulfoxide is 1: (5-15); the mass ratio of ACB-3 to cuprous oxide is 1: (0.2-0.5).
当然,certainly,
在ACB-5一步制得ACB-7后,还需优化结晶操作步骤,如优选的结晶溶剂为:甲醇,乙醇,异丙醇,正己烷,乙酸乙酯中的一种,优选甲醇。溶剂配比优选:After ACB-7 is prepared from ACB-5 in one step, the crystallization operation steps need to be optimized. For example, the preferred crystallization solvent is: one of methanol, ethanol, isopropyl alcohol, n-hexane, and ethyl acetate, with methanol being preferred. Optimal solvent ratio:
按照ACB-5为基准来核算,结晶溶剂与ACB-3的质量比:1:(3-6),优选1:(1-4)。Calculated based on ACB-5, the mass ratio of the crystallization solvent to ACB-3 is: 1: (3-6), preferably 1: (1-4).
按照ACB-3为基准来核算,结晶溶剂与ACB-3的质量比:1:(1-5),优选1:(1-4)。Calculated based on ACB-3, the mass ratio of the crystallization solvent to ACB-3 is: 1: (1-5), preferably 1: (1-4).
另外,本发明还提供一种由ACB-5制得ACB-7的方法,本发明实施例给出由ACB-5一步制得ACB-7具体操作步骤。In addition, the present invention also provides a method for preparing ACB-7 from ACB-5. The embodiments of the present invention provide specific operating steps for preparing ACB-7 from ACB-5 in one step.
本发明提供的由ACB-3连续制得ACB-7的整个过程优选溶剂为乙酸乙酯,其中,在ACB- 5制得后,还可以对乙酸乙酯溶剂进行循环套用。如将ACB-5的乙酸乙酯溶液进行部分蒸发回用。具体蒸发量根据便于工艺使用原则来确定,如一般是蒸至溶液保留一半左右。The preferred solvent for the entire process of continuously producing ACB-7 from ACB-3 provided by the present invention is ethyl acetate. After the ACB-5 is produced, the ethyl acetate solvent can also be recycled. For example, the ethyl acetate solution of ACB-5 can be partially evaporated for reuse. The specific evaporation amount is determined based on the principle of convenience for process use. For example, it is generally evaporated until about half of the solution is retained.
本发明的有益效果:Beneficial effects of the present invention:
本发明提供的一种氧头孢烯母核中间体的制备方法,由ACB-3连续制得ACB-7,操作简单,通过连续反应减少中间环节提纯,提高收率,且溶剂可以循环套用,反应过程还避免使用剧毒或强腐蚀型试剂,最终高收率得到目标产物。该技术已成功应用于工业化生产,具有非常高的经济和环保价值。The invention provides a method for preparing an oxycephem core intermediate, which continuously prepares ACB-7 from ACB-3. The operation is simple, the intermediate links for purification are reduced through continuous reactions, and the yield is improved. Moreover, the solvent can be recycled and the reaction The process also avoids the use of highly toxic or corrosive reagents, and ultimately obtains the target product in high yield. This technology has been successfully used in industrial production and has very high economic and environmental value.
图1为实施例1.1的产物ACB-7的HPLC图谱。Figure 1 is the HPLC spectrum of the product ACB-7 of Example 1.1.
图2为实施例1.1的产物ACB-7的核磁共振图谱。Figure 2 is the NMR spectrum of the product ACB-7 of Example 1.1.
图3为实施例3.1的产物ACB-4的HPLC图谱。Figure 3 is the HPLC spectrum of the product ACB-4 of Example 3.1.
图4为实施例3.1的产物ACB-4的核磁共振图谱。Figure 4 is the nuclear magnetic resonance spectrum of the product ACB-4 of Example 3.1.
图5为实施例4.1的产物ACB-5的HPLC图谱。Figure 5 is the HPLC spectrum of the product ACB-5 of Example 4.1.
图6为实施例4.1的产物ACB-5的核磁共振图谱。Figure 6 is the nuclear magnetic resonance spectrum of the product ACB-5 of Example 4.1.
图7为本发明从ACB-5制得ACB-7的反应过程图谱。Figure 7 is a diagram of the reaction process of preparing ACB-7 from ACB-5 according to the present invention.
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only some, not all, of the embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative efforts fall within the scope of protection of the present invention.
下列实施例中的原材料来源:Sources of raw materials in the following examples:
下面结合实施例对本发明做进一步说明。The present invention will be further described below in conjunction with examples.
实施例1:由ACB-3连续反应制得ACB-7Example 1: Preparation of ACB-7 by continuous reaction of ACB-3
实施例1.1Example 1.1
向反应器中加入90gACB-3(0.19mol)和1300g乙酸乙酯,搅拌至ACB-3完全溶解,向反应器中通入20g氯气(0.285mol),温度控制在30℃,搅拌反应料液3h。HPLC检测原料ACB-3残余<0.5%,加入碳酸氢钠和亚硫酸钠溶液洗涤。反应液静置分层,分出有机相乙酸乙酯相用纯化水洗涤,饱和盐水洗涤,硫酸镁干燥备用。离心分离硫酸镁,离心液氮气保护,加入34.2g碘化钠(0.228mol)搅拌反应液1.5h,温度控制为35℃,反应完全后把反应液加入到碳酸氢钠和亚硫酸钠碱液中,反应液静置分层,分出有机相乙酸乙酯层用用纯化水洗涤,饱和盐水涤,硫酸镁干燥,离心,离心液蒸出部分乙酸乙酯后为备用的ACB-5的乙酸乙酯相。蒸发出的乙酸乙酯干燥套用。向新反应器中加入1000g二甲基亚砜和43g氧化亚铜以及6.0g对甲苯磺酸,温度控制在12℃,反应液搅拌30min后加入ACB-5的乙酸乙酯相。温度控制在12℃,反应3h,开始升温至45℃继续搅拌反应2h,将反应液降温至0℃,向反应液中加入冰水和活性炭,搅拌30min后,离心,乙酸乙酯洗涤,离心液分层,分出有机相乙酸乙酯层,用5%碳酸氢钠溶液洗涤至中性,再用纯化水洗涤,饱和盐水洗涤,浓缩乙酸乙酯,加入350g甲醇结晶,离心烘干得到目标产物氧头孢烯母核中间体ACB-7白色粉状77.6g纯度98.8%,总收率84.8%。ACB-7的HPLC图谱见图1,核磁共振图谱见图2,
1H NMR(400MHz,DMSO-d
6)δ9.32(d,J=7.9Hz,1H),7.87–7.80(m,2H),7.55–7.44(m,4H),7.42–7.25(m,8H),6.89(s,1H),5.49(d,J=2.0Hz,2H),5.40(s,1H),5.35(d,J=0.9Hz,1H),4.79(dd,J=7.8,0.9Hz,1H),4.42(d,J=13.3Hz,1H),4.20(d,J=13.2Hz,1H),2.37(s,3H).
Add 90g ACB-3 (0.19mol) and 1300g ethyl acetate to the reactor, stir until ACB-3 is completely dissolved, pass 20g chlorine gas (0.285mol) into the reactor, control the temperature at 30°C, and stir the reaction liquid for 3 hours. . HPLC detects that the raw material ACB-3 residue is <0.5%, and adds sodium bicarbonate and sodium sulfite solutions for washing. The reaction solution was allowed to stand and separated into layers, and the organic phase, ethyl acetate phase, was separated, washed with purified water, washed with saturated brine, and dried over magnesium sulfate for later use. Centrifuge the magnesium sulfate, and protect the centrifugal liquid with nitrogen. Add 34.2g sodium iodide (0.228mol) and stir the reaction solution for 1.5 hours. The temperature is controlled at 35°C. After the reaction is complete, add the reaction solution to sodium bicarbonate and sodium sulfite alkali solution, and react. The liquid was allowed to stand for layering, and the organic phase, the ethyl acetate layer, was separated and washed with purified water, washed with saturated brine, dried over magnesium sulfate, centrifuged, and part of the ethyl acetate was evaporated from the centrifuged liquid to obtain the ethyl acetate phase of ACB-5 for later use. . The evaporated ethyl acetate was dried and used. Add 1000g dimethyl sulfoxide, 43g cuprous oxide and 6.0g p-toluenesulfonic acid to the new reactor. Control the temperature at 12°C. Stir the reaction solution for 30 minutes and then add the ethyl acetate phase of ACB-5. Control the temperature at 12°C and react for 3 hours. Start to raise the temperature to 45°C and continue stirring for 2 hours. Cool the reaction solution to 0°C. Add ice water and activated carbon to the reaction solution. After stirring for 30 minutes, centrifuge and wash with ethyl acetate. Layer the layers, separate the organic phase ethyl acetate layer, wash with 5% sodium bicarbonate solution until neutral, then wash with purified water, wash with saturated brine, concentrate the ethyl acetate, add 350g methanol to crystallize, centrifuge and dry to obtain the target product 77.6g of oxycephem core intermediate ACB-7 in white powder form has a purity of 98.8% and a total yield of 84.8%. The HPLC spectrum of ACB-7 is shown in Figure 1, and the nuclear magnetic resonance spectrum is shown in Figure 2. 1 H NMR (400MHz, DMSO-d 6 ) δ9.32 (d, J = 7.9 Hz, 1H), 7.87–7.80 (m, 2H) ,7.55–7.44(m,4H),7.42–7.25(m,8H),6.89(s,1H),5.49(d,J=2.0Hz,2H),5.40(s,1H),5.35(d,J =0.9Hz,1H),4.79(dd,J=7.8,0.9Hz,1H),4.42(d,J=13.3Hz,1H),4.20(d,J=13.2Hz,1H),2.37(s,3H ).
实施例1.2Example 1.2
向反应器中加入90gACB-3(0.19mol)和900g乙酸乙酯,搅拌至ACB-3完全溶解,向反应器中通入20g氯气(0.285mol),温度控制在30℃,搅拌反应料液3h。HPLC检测原料ACB-3残余<0.5%,加入碳酸氢钠和亚硫酸钠溶液洗涤。反应液静置分层,分出有机相乙酸乙酯相用纯化水洗涤,饱和盐水洗涤,硫酸镁干燥备用。离心分离硫酸镁,离心液氮气保护,加入48.5g碘化钾(0.292mol)搅拌反应液1.5h,温度控制为30℃,反应完全后把反应液加入到碳酸氢钠和亚硫酸钠碱液中,反应液静置分层,分出有机相乙酸乙酯层用用纯化水洗涤,饱和盐水涤,硫酸镁干燥,离心,离心液蒸出部分乙酸乙酯后为备用的ACB-5的乙酸乙酯相。蒸发出的乙酸乙酯干燥套用。向新反应器中加入500g二甲基亚砜和40g氧化亚铜以及10.8g对甲苯磺酸,温度控制在15℃,反应液搅拌30min后加入ACB-5的乙酸乙酯相。温度控制在15℃,反应3h,开始升温至50℃继续搅拌反应2h,将反应液降温至3℃,向反应液中加入冰水和活性炭,搅拌30min后,离心,乙酸乙酯洗涤,离心液分层,分出有机相乙酸乙酯层,用5%碳酸氢钠溶液洗涤至中性,再用纯化水洗涤,饱和盐水洗涤,浓缩乙酸乙酯,加入300g甲醇结晶,离心烘干得到目标产物氧头孢烯母核中间体ACB-7白色粉状70.4g,纯度98.4%,总收率76.9%。Add 90g ACB-3 (0.19mol) and 900g ethyl acetate to the reactor, stir until ACB-3 is completely dissolved, pass 20g chlorine gas (0.285mol) into the reactor, control the temperature at 30°C, and stir the reaction liquid for 3 hours. . HPLC detects that the raw material ACB-3 residue is <0.5%, and adds sodium bicarbonate and sodium sulfite solutions for washing. The reaction solution was allowed to stand and separated into layers, and the organic phase, ethyl acetate phase, was separated, washed with purified water, washed with saturated brine, and dried over magnesium sulfate for later use. Centrifuge the magnesium sulfate, and protect the centrifugal liquid with nitrogen. Add 48.5g potassium iodide (0.292mol) and stir the reaction solution for 1.5 hours. The temperature is controlled at 30°C. After the reaction is complete, the reaction solution is added to the sodium bicarbonate and sodium sulfite alkali solution. The reaction solution is allowed to stand still. Separate the layers, separate the organic phase and the ethyl acetate layer, wash with purified water, wash with saturated brine, dry over magnesium sulfate, centrifuge, and evaporate part of the ethyl acetate from the centrifugal liquid to obtain the ethyl acetate phase of ACB-5 for later use. The evaporated ethyl acetate was dried and used. Add 500g dimethyl sulfoxide, 40g cuprous oxide and 10.8g p-toluenesulfonic acid to the new reactor. Control the temperature at 15°C. Stir the reaction solution for 30 minutes and then add the ethyl acetate phase of ACB-5. Control the temperature at 15°C and react for 3 hours. Start to raise the temperature to 50°C and continue stirring the reaction for 2 hours. Cool the reaction solution to 3°C. Add ice water and activated carbon to the reaction solution. After stirring for 30 minutes, centrifuge and wash with ethyl acetate. Layer the layers, separate the organic phase ethyl acetate layer, wash with 5% sodium bicarbonate solution until neutral, then wash with purified water, wash with saturated brine, concentrate the ethyl acetate, add 300g methanol to crystallize, centrifuge and dry to obtain the target product The oxycephem core intermediate ACB-7 is 70.4g in white powder form, with a purity of 98.4% and a total yield of 76.9%.
实施例1.3Example 1.3
向反应器中加入90gACB-3(0.19mol)和900g乙酸乙酯,搅拌至ACB-3完全溶解,向反应器中通入20g氯气(0.285mol),温度控制在35℃,搅拌反应料液3h。HPLC检测原料ACB-3残余<0.5%,加入碳酸氢钠和亚硫酸钠溶液洗涤。反应液静置分层,分出有机相乙酸乙酯相用纯化水洗涤,饱和盐水洗涤,硫酸镁干燥备用。离心分离硫酸镁,离心液氮气保护,加入28.5g碘化钠(0.19mol)搅拌反应液1.5h,温度控制为35℃,反应完全后把反应液加入到碳酸氢钠和亚硫酸钠碱液中,反应液静置分层,分出有机相乙酸乙酯层用用纯化水洗涤,饱和盐水涤,硫酸镁干燥,离心,离心液蒸出部分乙酸乙酯后为备用的ACB-5的乙酸乙酯相。蒸发出的乙酸乙酯干燥套用。向新反应器中加入450g二甲基亚砜和45g氧化亚铜以及9.0g对甲苯磺酸,温度控制在10℃,反应液搅拌30min后加入ACB-5的乙酸乙酯相。温度控制在10℃,反应2.5h,开始升温至45℃继续搅拌反应2h,将反应液降温至3℃,向反应液中加入冰水和活性炭,搅拌30min后,离心,乙酸乙酯洗涤,离心液分层,分出有机相乙酸乙酯层,用5%碳酸氢钠溶液洗涤至中性,再用纯化水洗涤,饱和盐水洗涤,浓缩乙酸乙酯,加入300g甲醇结晶,离心烘干得到目标产物氧头孢烯母核中间体ACB-7白色粉状76.9g,纯度98.6%,总收率83.9%。
1H NMR(400MHz,DMSO-d
6)δ9.32(d,J=7.9Hz,1H),7.87–7.80(m,2H),7.55–7.44(m,4H),7.42–7.25(m,8H),6.89(s,1H),5.49(d,J=2.0Hz,2H),5.40(s,1H), 5.35(d,J=0.9Hz,1H),4.79(dd,J=7.8,0.9Hz,1H),4.42(d,J=13.3Hz,1H),4.20(d,J=13.2Hz,1H),2.37(s,3H).
Add 90g ACB-3 (0.19mol) and 900g ethyl acetate to the reactor, stir until ACB-3 is completely dissolved, pass 20g chlorine gas (0.285mol) into the reactor, control the temperature at 35°C, and stir the reaction liquid for 3 hours. . HPLC detects that the raw material ACB-3 residue is <0.5%, and adds sodium bicarbonate and sodium sulfite solutions for washing. The reaction solution was allowed to stand and separated into layers, and the organic phase, ethyl acetate phase, was separated, washed with purified water, washed with saturated brine, and dried over magnesium sulfate for later use. Centrifuge the magnesium sulfate, and protect the centrifugal liquid with nitrogen. Add 28.5g sodium iodide (0.19mol) and stir the reaction solution for 1.5 hours. The temperature is controlled at 35°C. After the reaction is complete, add the reaction solution to sodium bicarbonate and sodium sulfite alkali solution, and react. The liquid was allowed to stand for layering, and the organic phase, the ethyl acetate layer, was separated and washed with purified water, washed with saturated brine, dried over magnesium sulfate, centrifuged, and part of the ethyl acetate was evaporated from the centrifuged liquid to obtain the ethyl acetate phase of ACB-5 for later use. . The evaporated ethyl acetate was dried and used. Add 450g dimethyl sulfoxide, 45g cuprous oxide and 9.0g p-toluenesulfonic acid to the new reactor. Control the temperature at 10°C. Stir the reaction solution for 30 minutes and then add the ethyl acetate phase of ACB-5. Control the temperature at 10°C and react for 2.5 hours. Start to raise the temperature to 45°C and continue stirring the reaction for 2 hours. Cool the reaction solution to 3°C. Add ice water and activated carbon to the reaction solution. After stirring for 30 minutes, centrifuge, wash with ethyl acetate, and centrifuge. Separate the liquid layer, separate the organic phase ethyl acetate layer, wash with 5% sodium bicarbonate solution until neutral, then wash with purified water, wash with saturated brine, concentrate the ethyl acetate, add 300g methanol to crystallize, centrifuge and dry to obtain the target The product oxycephem core intermediate ACB-7 is 76.9g in the form of white powder, with a purity of 98.6% and a total yield of 83.9%. 1 H NMR (400MHz, DMSO-d 6 ) δ9.32 (d, J = 7.9 Hz, 1H), 7.87–7.80 (m, 2H), 7.55–7.44 (m, 4H), 7.42–7.25 (m, 8H) ),6.89(s,1H),5.49(d,J=2.0Hz,2H),5.40(s,1H), 5.35(d,J=0.9Hz,1H),4.79(dd,J=7.8,0.9Hz ,1H),4.42(d,J=13.3Hz,1H),4.20(d,J=13.2Hz,1H),2.37(s,3H).
实施例1.4Example 1.4
向反应器中加入90gACB-3(0.19mol)和1300g乙酸乙酯,搅拌至ACB-3完全溶解,向反应器中通入21g氯气(0.285mol),温度控制在45℃,搅拌反应料液3h。HPLC检测原料ACB-3残余<0.5%,加入碳酸氢钠和亚硫酸钠溶液洗涤。反应液静置分层,分出有机相乙酸乙酯相用纯化水洗涤,饱和盐水洗涤,硫酸镁干燥备用。离心分离硫酸镁,离心液氮气保护,加入34.2g碘化钠(0.228mol)搅拌反应液1.5h,温度控制为35℃,反应完全后把反应液加入到碳酸氢钠和亚硫酸钠碱液中,反应液静置分层,分出有机相乙酸乙酯层用用纯化水洗涤,饱和盐水涤,硫酸镁干燥,离心,离心液蒸出部分乙酸乙酯后为备用的ACB-5的乙酸乙酯相。蒸发出的乙酸乙酯干燥套用。向新反应器中加入1080g二甲基亚砜和45g氧化亚铜以及16g对甲氧基苯磺酸,温度控制在15℃,反应液搅拌30min后加入ACB-5的乙酸乙酯相。温度控制在15℃,反应2h,开始升温至55℃继续搅拌反应2h,将反应液降温至0℃,向反应液中加入冰水和活性炭,搅拌30min后,离心,乙酸乙酯洗涤,离心液分层,分出有机相乙酸乙酯层,用5%碳酸氢钠溶液洗涤至中性,再用纯化水洗涤,饱和盐水洗涤,浓缩乙酸乙酯,加入350g甲醇结晶,离心烘干得到目标产物氧头孢烯母核中间体ACB-7白色粉状65.4g纯度97.6%,总收率71.3%。Add 90g ACB-3 (0.19mol) and 1300g ethyl acetate to the reactor, stir until ACB-3 is completely dissolved, pass 21g chlorine gas (0.285mol) into the reactor, control the temperature at 45°C, and stir the reaction liquid for 3 hours. . HPLC detects that the raw material ACB-3 residue is <0.5%, and adds sodium bicarbonate and sodium sulfite solutions for washing. The reaction solution was allowed to stand and separated into layers, and the organic phase, ethyl acetate phase, was separated, washed with purified water, washed with saturated brine, and dried over magnesium sulfate for later use. Centrifuge the magnesium sulfate, and protect the centrifugal liquid with nitrogen. Add 34.2g sodium iodide (0.228mol) and stir the reaction solution for 1.5 hours. The temperature is controlled at 35°C. After the reaction is complete, add the reaction solution to sodium bicarbonate and sodium sulfite alkali solution, and react. The liquid was allowed to stand for layering, and the organic phase, the ethyl acetate layer, was separated and washed with purified water, washed with saturated brine, dried over magnesium sulfate, centrifuged, and part of the ethyl acetate was evaporated from the centrifuged liquid to obtain the ethyl acetate phase of ACB-5 for later use. . The evaporated ethyl acetate was dried and used. Add 1080g dimethyl sulfoxide, 45g cuprous oxide and 16g p-methoxybenzenesulfonic acid to the new reactor. Control the temperature at 15°C. Stir the reaction solution for 30 minutes and then add the ethyl acetate phase of ACB-5. Control the temperature at 15°C and react for 2 hours. Start to raise the temperature to 55°C and continue stirring for 2 hours. Cool the reaction solution to 0°C. Add ice water and activated carbon to the reaction solution. After stirring for 30 minutes, centrifuge and wash with ethyl acetate. Layer the layers, separate the organic phase ethyl acetate layer, wash with 5% sodium bicarbonate solution until neutral, then wash with purified water, wash with saturated brine, concentrate the ethyl acetate, add 350g methanol to crystallize, centrifuge and dry to obtain the target product 65.4g of oxycephem core intermediate ACB-7 white powder has a purity of 97.6% and a total yield of 71.3%.
实施例1.5Example 1.5
向反应器中加入90gACB-3(0.19mol)和1300g乙酸乙酯,搅拌至ACB-3完全溶解,向反应器中通入20g氯气(0.285mol),温度控制在35℃,搅拌反应料液3h。HPLC检测原料ACB-3残余<0.5%,加入碳酸氢钠和亚硫酸钠溶液洗涤。反应液静置分层,分出有机相乙酸乙酯相用纯化水洗涤,饱和盐水洗涤,硫酸镁干燥备用。离心分离硫酸镁,离心液氮气保护,加入34.3g碘化钠(0.228mol)搅拌反应液1.5h,温度控制为35℃,反应完全后把反应液加入到碳酸氢钠和亚硫酸钠碱液中,反应液静置分层,分出有机相乙酸乙酯层用用纯化水洗涤,饱和盐水涤,硫酸镁干燥,离心,离心液蒸出部分乙酸乙酯后为备用的ACB-5的乙酸乙酯相。蒸发出的乙酸乙酯干燥套用。向新反应器中加入1080g二甲基亚砜和45g氧化亚铜以及6.5g对甲氧基苯磺酸,温度控制在15℃,反应液搅拌30min后加入ACB-5的乙酸乙酯相。温度控制在15℃,反应2h,开始升温至50℃继续搅拌反应2h,将反应液降温至0℃,向反应液中加入冰水和活性炭,搅拌30min后,离心,乙酸乙酯洗涤,离心液分层,分出有机相 乙酸乙酯层,用5%碳酸氢钠溶液洗涤至中性,再用纯化水洗涤,饱和盐水洗涤,浓缩乙酸乙酯,加入400g乙醇结晶,离心烘干得到目标产物氧头孢烯母核中间体ACB-7白色粉状77.1g纯度98.5%总收率84.2%。Add 90g ACB-3 (0.19mol) and 1300g ethyl acetate to the reactor, stir until ACB-3 is completely dissolved, pass 20g chlorine gas (0.285mol) into the reactor, control the temperature at 35°C, and stir the reaction liquid for 3 hours. . HPLC detects that the raw material ACB-3 residue is <0.5%, and adds sodium bicarbonate and sodium sulfite solutions for washing. The reaction solution was allowed to stand and separated into layers, and the organic phase, ethyl acetate phase, was separated, washed with purified water, washed with saturated brine, and dried over magnesium sulfate for later use. Centrifuge the magnesium sulfate, and protect the centrifugal liquid with nitrogen. Add 34.3g sodium iodide (0.228mol) and stir the reaction solution for 1.5 hours. The temperature is controlled at 35°C. After the reaction is complete, add the reaction solution to sodium bicarbonate and sodium sulfite alkali solution, and react. The liquid was allowed to stand for layering, and the organic phase, the ethyl acetate layer, was separated and washed with purified water, washed with saturated brine, dried over magnesium sulfate, centrifuged, and part of the ethyl acetate was evaporated from the centrifuged liquid to obtain the ethyl acetate phase of ACB-5 for later use. . The evaporated ethyl acetate was dried and used. Add 1080g dimethyl sulfoxide, 45g cuprous oxide and 6.5g p-methoxybenzenesulfonic acid to the new reactor. Control the temperature at 15°C. Stir the reaction solution for 30 minutes and then add the ethyl acetate phase of ACB-5. Control the temperature at 15°C and react for 2 hours. Start to raise the temperature to 50°C and continue stirring for 2 hours. Cool the reaction solution to 0°C. Add ice water and activated carbon to the reaction solution. After stirring for 30 minutes, centrifuge and wash with ethyl acetate. Layer the layers, separate the organic phase ethyl acetate layer, wash with 5% sodium bicarbonate solution until neutral, then wash with purified water, wash with saturated brine, concentrate the ethyl acetate, add 400g of ethanol to crystallize, centrifuge and dry to obtain the target product 77.1g of oxycephem core intermediate ACB-7 white powder, purity 98.5%, total yield 84.2%.
实施例2:由ACB-5一步制得ACB-7Example 2: Preparing ACB-7 from ACB-5 in one step
在反应器中加入ACB-5和乙酸乙酯,再加入二甲基亚砜/氧化亚铜/苯磺酸系列,控制初始反应温度和反应时间;HPLC检测ACB-5反应完全后,开始升温反应,将反应液降温至3℃,向反应液中加入冰水和活性炭,搅拌30min后,离心,乙酸乙酯洗涤,离心液分层,分出有机相乙酸乙酯层,用5%碳酸氢钠溶液洗涤至中性,再用纯化水洗涤,饱和盐水洗涤,浓缩乙酸乙酯,加入甲醇结晶,离心烘干得到目标产物氧头孢烯母核中间体ACB-7白色粉状。Add ACB-5 and ethyl acetate to the reactor, then add the dimethyl sulfoxide/cuprous oxide/benzenesulfonic acid series to control the initial reaction temperature and reaction time; after HPLC detects that the ACB-5 reaction is complete, start the temperature-raising reaction , cool the reaction solution to 3°C, add ice water and activated carbon to the reaction solution, stir for 30 minutes, centrifuge, wash with ethyl acetate, separate the centrifugal solution, separate the organic phase ethyl acetate layer, and use 5% sodium bicarbonate The solution was washed until neutral, then washed with purified water, washed with saturated brine, concentrated with ethyl acetate, crystallized by adding methanol, centrifuged and dried to obtain the target product oxycephem core intermediate ACB-7 as white powder.
下表为各种工艺参数的调节得到的ACB-7的收率和纯度结果。其中收率为ACB-7与ACB-5的质量比。The following table shows the yield and purity results of ACB-7 obtained by adjusting various process parameters. The yield is the mass ratio of ACB-7 to ACB-5.
本发明为实现由ACB-3连续制得ACB-7,并能够保证ACB-7的收率和纯度足够高,需进行各中间产物制备工艺的优化,实施例3和实施例4给出部分实验例:In order to realize the continuous production of ACB-7 from ACB-3 and ensure that the yield and purity of ACB-7 are high enough, the present invention needs to optimize the preparation process of each intermediate product. Examples 3 and 4 give some experiments. example:
实施例3.由ACB-3制备ACB-4的实施例Example 3. Example of preparation of ACB-4 from ACB-3
向反应器中加入ACB-3和乙酸乙酯,搅拌至ACB-3完全溶解,向反应器中通入氯气,控制反应温度和时间,得到ACB-4溶液,经过结晶干燥得到ACB-4固体。下表为各种工艺参数的调节得到的ACB-4的收率和纯度结果。其中收率为ACB-4与ACB-3的质量比。Add ACB-3 and ethyl acetate to the reactor, stir until ACB-3 is completely dissolved, pass chlorine gas into the reactor, control the reaction temperature and time to obtain an ACB-4 solution, and obtain ACB-4 solid after crystallization and drying. The following table shows the yield and purity results of ACB-4 obtained by adjusting various process parameters. The yield is the mass ratio of ACB-4 to ACB-3.
实施例3.1的ACB-4的HPLC图谱见图3,核磁共振图谱见图4,
1H NMR(400MHz,DMSO-d
6)δ7.75–7.68(m,2H),7.36–7.20(m,12H),6.85(s,1H),6.16(d,J=3.2Hz,1H),5.40(d,J=3.2Hz,1H),5.15–5.05(m,2H),2.36(s,3H),1.76(s,3H).
The HPLC spectrum of ACB-4 of Example 3.1 is shown in Figure 3, and the nuclear magnetic resonance spectrum is shown in Figure 4. 1 H NMR (400MHz, DMSO-d 6 ) δ7.75–7.68 (m, 2H), 7.36–7.20 (m, 12H) ),6.85(s,1H),6.16(d,J=3.2Hz,1H),5.40(d,J=3.2Hz,1H),5.15–5.05(m,2H),2.36(s,3H),1.76 (s,3H).
实施例4.由ACB-4制备ACB-5的工艺优化实施例Example 4. Process optimization example for preparing ACB-5 from ACB-4
在反应器中加入ACB-4、碘化物、反应溶剂、控制一定的反应温度和反应时间,反应完全后把反应液加入到碳酸氢钠和亚硫酸钠碱液中,反应液静置分层,分出有机相层用用纯化水洗涤,饱和盐水涤,硫酸镁干燥,离心,离心液经过结晶干燥得到ACB-5固体。下表为各种工艺参数的调节得到的ACB-5的收率和纯度结果。其中收率为ACB-5与ACB-4的质量比。Add ACB-4, iodide, and reaction solvent to the reactor, and control a certain reaction temperature and reaction time. After the reaction is complete, add the reaction solution to sodium bicarbonate and sodium sulfite alkali solution, and let the reaction solution stand for stratification and separate. The organic phase layer was washed with purified water, washed with saturated brine, dried over magnesium sulfate, and centrifuged. The centrifuged liquid was crystallized and dried to obtain ACB-5 solid. The following table shows the yield and purity results of ACB-5 obtained by adjusting various process parameters. The yield is the mass ratio of ACB-5 to ACB-4.
实施例4.1的ACB-5的HPLC图谱见图5,核磁共振图谱见图6,
1H NMR(400MHz,DMSO-d
6)δ7.76–7.69(m,2H),7.37–7.20(m,13H),6.86(s,1H),6.14(d,J=3.2Hz,1H),5.71(s,1H),5.40(d,J=3.3Hz,1H),5.27(d,J=13.1Hz,2H),4.39(s,2H),2.35(s,3H).
The HPLC spectrum of ACB-5 in Example 4.1 is shown in Figure 5, and the nuclear magnetic resonance spectrum is shown in Figure 6. 1 H NMR (400MHz, DMSO-d 6 ) δ7.76–7.69 (m, 2H), 7.37–7.20 (m, 13H) ),6.86(s,1H),6.14(d,J=3.2Hz,1H),5.71(s,1H),5.40(d,J=3.3Hz,1H),5.27(d,J=13.1Hz,2H ),4.39(s,2H),2.35(s,3H).
以上所述实例仅表达本发明的几种实施方案,其描述为具体和详细。上述为本发明创造的较佳实施例而已,并不用以限制本发明创造,凡在本发明创造的精神和原则之内,所作的任何修改、等同替换等,均应包含在本发明创造的保护范围之内。对于本领域的普通技术人员来说,在不脱离本发明构思的前提下还可以做出若干变形和改进,这些都属于本发明的保护范围,因此本发明专利的保护范围应以所附权利要求为准。The examples described above represent only several embodiments of the invention, which are described with specificity and detail. The above are only preferred embodiments of the present invention, and are not intended to limit the present invention. Any modifications, equivalent substitutions, etc. made within the spirit and principles of the present invention shall be included in the protection of the present invention. within the range. For those of ordinary skill in the art, several modifications and improvements can be made without departing from the concept of the present invention. These all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention should be determined by the appended claims. shall prevail.
Claims (15)
- 根据权利要求1所述的一种氧头孢烯母核中间体的制备方法,其特征在于:由ACB-3制得ACB-4的步骤中,ACB-3:氯气摩尔比=1:(1-2.5),优选1:(1-2),1:(1-1.5)或1:(1-1.2)。The preparation method of an oxycephem core intermediate according to claim 1, characterized in that: in the step of preparing ACB-4 from ACB-3, the molar ratio of ACB-3: chlorine = 1: (1- 2.5), preferably 1: (1-2), 1: (1-1.5) or 1: (1-1.2).
- 根据权利要求1所述的一种氧头孢烯母核中间体的制备方法,其特征在于:由ACB-3制得ACB-4的步骤中,温度控制在30-45℃。The method for preparing an oxycephem core intermediate according to claim 1, characterized in that in the step of preparing ACB-4 from ACB-3, the temperature is controlled at 30-45°C.
- 根据权利要求1所述的一种氧头孢烯母核中间体的制备方法,其特征在于:由ACB-4制得ACB-5的步骤中,碘化物选择NaI或KI,ACB-3:碘化物摩尔比=1:(1-1.5)。The preparation method of an oxycephem core intermediate according to claim 1, characterized in that: in the step of preparing ACB-5 from ACB-4, the iodide is NaI or KI, and ACB-3: iodide Molar ratio = 1: (1-1.5).
- 根据权利要求1所述的一种氧头孢烯母核中间体的制备方法,其特征在于:由ACB-4制得ACB-5的步骤中,温度控制为20-45℃,优选30-35℃。The preparation method of an oxycephem core intermediate according to claim 1, characterized in that: in the step of preparing ACB-5 from ACB-4, the temperature is controlled to 20-45°C, preferably 30-35°C. .
- 根据权利要求1所述的一种氧头孢烯母核中间体的制备方法,其特征在于:由ACB-5制得ACB-7的步骤,选择氧化亚铜/二甲基亚砜/苯磺酸类酸性催化剂体系。The preparation method of an oxycephem core intermediate according to claim 1, characterized in that: in the step of preparing ACB-7 from ACB-5, cuprous oxide/dimethyl sulfoxide/benzenesulfonic acid is selected. Acid-like catalyst system.
- 根据权利要求6所述的一种氧头孢烯母核中间体的制备方法,其特征在于:反应温度采用阶梯温度,初始温度控制在10-15℃时反应2-3h之后,升温 至40-55℃时反应0.5-2h。The preparation method of an oxycephem core intermediate according to claim 6, characterized in that: the reaction temperature adopts a step temperature, and the initial temperature is controlled at 10-15°C and after 2-3 hours of reaction, the temperature is raised to 40-55°C. The reaction takes 0.5-2h at ℃.
- 根据权利要求6所述的一种氧头孢烯母核中间体的制备方法,其特征在于:ACB-3与对甲基苯磺酸质量比为1:(0.03-0.5),优选1:(0.03-0.15)。The preparation method of an oxycephem core intermediate according to claim 6, characterized in that: the mass ratio of ACB-3 to p-toluenesulfonic acid is 1: (0.03-0.5), preferably 1: (0.03 -0.15).
- 根据权利要求6所述的一种氧头孢烯母核中间体的制备方法,其特征在于:ACB-3与溶剂二甲基亚砜的质量比为1:(5-15)。The preparation method of an oxycephem core intermediate according to claim 6, characterized in that: the mass ratio of ACB-3 to solvent dimethyl sulfoxide is 1: (5-15).
- 根据权利要求6所述的一种氧头孢烯母核中间体的制备方法,其特征在于:ACB-3与氧化亚铜的质量比为1:(0.2-0.5)。The preparation method of an oxycephem core intermediate according to claim 6, characterized in that: the mass ratio of ACB-3 to cuprous oxide is 1: (0.2-0.5).
- 根据权利要求1所述的一种氧头孢烯母核中间体的制备方法,其特征在于:在ACB-5制得ACB-7后,结晶溶剂为甲醇,乙醇,异丙醇,正己烷,乙酸乙酯中的一种,溶剂与ACB-3的质量比:1:(1-5)。The preparation method of an oxycephem core intermediate according to claim 1, characterized in that: after ACB-7 is prepared from ACB-5, the crystallization solvent is methanol, ethanol, isopropyl alcohol, n-hexane, acetic acid One of the ethyl esters, the mass ratio of solvent to ACB-3: 1: (1-5).
- 根据权利要求1所述的一种氧头孢烯母核中间体的制备方法,其特征在于:整个反应过程选择溶剂为乙酸乙酯,且在ACB-5制得后,还可以对乙酸乙酯溶剂进行循环套用。The preparation method of an oxycephem core intermediate according to claim 1, characterized in that: the selected solvent for the entire reaction process is ethyl acetate, and after the ACB-5 is prepared, the ethyl acetate solvent can also be used Apply in a loop.
- 一种氧头孢烯母核中间体的制备方法,其特征在于:由ACB-5直接制得ACB-5,选择氧化亚铜/二甲基亚砜/苯磺酸类酸性催化剂体系反应式为:A method for preparing an oxycephem core intermediate, which is characterized in that ACB-5 is directly prepared from ACB-5, and the reaction formula of the cuprous oxide/dimethyl sulfoxide/benzenesulfonic acid acidic catalyst system is selected:
- 根据权利要求13所述的由ACB-5制得ACB-7的方法,其特征在于:反应温度采用阶梯温度,初始温度控制在10-15℃时反应2-3h之后,升温至40-60℃时反应0.5-2h。The method for preparing ACB-7 from ACB-5 according to claim 13, characterized in that: the reaction temperature adopts step temperature, and the initial temperature is controlled at 10-15°C and after 2-3 hours of reaction, the temperature is raised to 40-60°C. The reaction time is 0.5-2h.
- 根据权利要求14所述的由ACB-5制得ACB-7的方法,其特征在于: 反应物配比按照ACB-5为基准来核算,ACB-5与对甲基苯磺酸质量比为1:(0.02-0.45),优选1:(0.02-0.12),ACB-5与溶剂二甲基亚砜的质量比为1:(6-10),ACB-3与氧化亚铜的质量比为1:(0.27-0.45)。The method for preparing ACB-7 from ACB-5 according to claim 14, characterized in that: the reactant ratio is calculated based on ACB-5, and the mass ratio of ACB-5 to p-toluenesulfonic acid is 1 (0.02-0.45), preferably 1: (0.02-0.12), the mass ratio of ACB-5 to solvent dimethyl sulfoxide is 1: (6-10), the mass ratio of ACB-3 to cuprous oxide is 1 :(0.27-0.45).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210448502.5A CN114805395B (en) | 2022-04-27 | 2022-04-27 | Preparation method of oxacephem parent nucleus intermediate |
CN202210448502.5 | 2022-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023206607A1 true WO2023206607A1 (en) | 2023-11-02 |
Family
ID=82508168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/092235 WO2023206607A1 (en) | 2022-04-27 | 2022-05-11 | Method for preparing oxacephem parent nucleus intermediate |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114805395B (en) |
WO (1) | WO2023206607A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1030548B1 (en) * | 2023-07-11 | 2023-12-13 | Shaanxi Youbang Biopharma Tech Co Ltd | Process for producing an oxacephem-nucleus intermediate |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5944390A (en) * | 1982-09-07 | 1984-03-12 | Shionogi & Co Ltd | Preparation of oxazoline compound |
JPS61165365A (en) * | 1985-01-18 | 1986-07-26 | Sumitomo Seiyaku Kk | Novel production of beta-lactam compound |
JPS61246187A (en) * | 1985-09-05 | 1986-11-01 | Shionogi & Co Ltd | 1-oxadethiacepham compound |
US4721819A (en) * | 1986-12-30 | 1988-01-26 | Shell Oil Company | Process for the preparation of higher allylic ethers |
JP2005179336A (en) * | 2004-07-08 | 2005-07-07 | Shionogi & Co Ltd | MANUFACTURING METHOD FOR 1-OXACEPHALOSPORIN-7alpha-METHOXY-3-CHLOROMETHYL DERIVATIVE |
CN103254215A (en) * | 2013-05-24 | 2013-08-21 | 浙江东邦药业有限公司 | Preparation method of allyl chlorooxyl cephalosporin compound |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004168775A (en) * | 2002-11-08 | 2004-06-17 | Orchid Chemicals & Pharmaceuticals Ltd | Improving synthetic method of oxacephalosporin |
CN106188097B (en) * | 2016-07-08 | 2018-01-05 | 郑州大学 | A kind of preparation method of 3 chloromethyl oxacephems antibiotic parent nucleus |
-
2022
- 2022-04-27 CN CN202210448502.5A patent/CN114805395B/en active Active
- 2022-05-11 WO PCT/CN2022/092235 patent/WO2023206607A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5944390A (en) * | 1982-09-07 | 1984-03-12 | Shionogi & Co Ltd | Preparation of oxazoline compound |
JPS61165365A (en) * | 1985-01-18 | 1986-07-26 | Sumitomo Seiyaku Kk | Novel production of beta-lactam compound |
JPS61246187A (en) * | 1985-09-05 | 1986-11-01 | Shionogi & Co Ltd | 1-oxadethiacepham compound |
US4721819A (en) * | 1986-12-30 | 1988-01-26 | Shell Oil Company | Process for the preparation of higher allylic ethers |
JP2005179336A (en) * | 2004-07-08 | 2005-07-07 | Shionogi & Co Ltd | MANUFACTURING METHOD FOR 1-OXACEPHALOSPORIN-7alpha-METHOXY-3-CHLOROMETHYL DERIVATIVE |
CN103254215A (en) * | 2013-05-24 | 2013-08-21 | 浙江东邦药业有限公司 | Preparation method of allyl chlorooxyl cephalosporin compound |
Also Published As
Publication number | Publication date |
---|---|
CN114805395A (en) | 2022-07-29 |
CN114805395B (en) | 2023-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109776487B (en) | Preparation method of vinyl sulfate | |
EP3133061A1 (en) | Florfenicol synthesizing method | |
WO2023206607A1 (en) | Method for preparing oxacephem parent nucleus intermediate | |
CN112079742B (en) | Method for preparing lidocaine through continuous reaction | |
CN105085544A (en) | Synthesis method of tazobactam diphenylmethyl ester | |
CN115232103B (en) | Preparation method of cyclic sulfate | |
CN103058913A (en) | Method for synthesizing 5-isoindolone chloride | |
CN114671859B (en) | Preparation method of rosuvastatin calcium and intermediate thereof | |
RO121737B1 (en) | Process for preparing 5-carboxyphthalide and use thereof for producing citalopram | |
CN114380877B (en) | Preparation method of 2' -deoxy-2 ' -beta-fluoro-4 ' -azidocytidine | |
CN102267934A (en) | Method for preparing 6-carbomethoxy indolone | |
CN117362267A (en) | Method for preparing vinyl sulfate by catalysis | |
CN101774988B (en) | Vitamin C catalyzing and synthesizing method with solid phase bifunctional catalyst | |
CN111100042B (en) | Preparation method of 2-methoxy-5-sulfonamide benzoic acid | |
CN102491992A (en) | Method for preparing carbapenem type antibiotic key intermediate 4-BMA | |
CN114989075B (en) | Preparation method of etoricoxib intermediate | |
CN115073350B (en) | Preparation method of eremophilone | |
CN112479863B (en) | Method for preparing 2-methyl-4-chlorophenoxyacetic acid by catalyzing and chlorinating 2-methylphenoxy acetic acid | |
CN113801082B (en) | Preparation method of ranimivir octoate | |
CN117946013B (en) | Method for synthesizing 5, 6-dihalogen-3-aminopyrazine-2-methyl formate by one-pot method | |
CN116283798B (en) | Novel preparation method of urapidil | |
CN114315588B (en) | Preparation method of o-nitrobenzaldehyde | |
WO2021248764A1 (en) | Method for preparing laninamivir octanoate intermediate by means of one-pot synthesis | |
CN108383709A (en) | A kind of method that phase transfer catalysis process prepares high-purity Fenofibric Acid | |
CN101891666B (en) | Preparation method of intermediate of beta methylcarbapenem antibiotics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22939449 Country of ref document: EP Kind code of ref document: A1 |